Wealth Enhancement Advisory Services’s Cullinan Oncology CGEM Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	+11,168	New	+$166K	﹤0.01%	3576

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Wealth Enhancement Advisory Services's CGEM Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 11,168 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #3576 among its holdings.

183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

Wealth Enhancement Advisory Services held 11,168 shares of Cullinan Oncology worth $202K as of Q2 2026.
Cullinan Oncology was a new Wealth Enhancement Advisory Services position in Q2 2026.
Cullinan Oncology made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3576 holding.
183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.